How route of administration, bioavailability and local versus systemic effects influence route-specific PDE/HBEL assessments.
Shared manufacturing can create exposure through a route different from the route for which the source toxicology was generated. Route-to-route extrapolation is therefore a scientific interpretation problem, not merely a mathematical conversion.
Prefer relevant route-specific evidence
When route changes local tissue exposure or systemic availability, data from the target route are particularly valuable.
Bioavailability
Differences in absorption can materially change internal exposure and can justify adjustment when scientifically supported.
Local versus systemic effects
Dermal, ocular, inhalation, intrathecal and other specialized routes can involve local effects that are not captured by a systemic PoD.
Documentation
The report should make the source route, target route, critical effect, pharmacokinetic evidence and uncertainty explicit.
Frequently asked questions
Does every route require a separate HBEL?
No. Separate values are considered when route differences are material.
Is bioavailability alone sufficient?
No. Local effects, metabolism, tissue exposure and the nature of the critical effect also matter.
Can oral data support a parenteral HBEL?
Sometimes, with a scientifically justified extrapolation.
Should the applicable route be stated in the report?
Yes, so the limit can be interpreted correctly.
